$tr2['classname']

肺癌

$tr2['classname']

乳腺癌

$tr2['classname']

结直肠癌

$tr2['classname']

前列腺癌

$tr2['classname']

甲状腺癌

$tr2['classname']

宫颈癌

$tr2['classname']

胃癌

$tr2['classname']

肝癌

$tr2['classname']

胆囊癌

$tr2['classname']

卵巢癌

$tr2['classname']

食管癌

$tr2['classname']

胰腺癌

$tr2['classname']

膀胱癌

$tr2['classname']

淋巴瘤

$tr2['classname']

子宫内膜癌

$tr2['classname']

肾癌

$tr2['classname']

罕见肿瘤

首页 > TAG信息列表 > cemiplimab

西米普利单抗|上市信息

PD-1免疫抑制剂Libtayo( 西米普利单抗,cemiplimab)获FDA批准,非小

西米普利单抗|最新研究

《柳叶刀》子刊:免疫治疗时间前移,1/3肝癌患者接受新辅助治疗肿瘤
 降低死亡风险31%,宫颈癌创新PD-1西米普利单抗(Libtayo,cemiplimab)